These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
126 related items for PubMed ID: 22670722
1. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. Juillerat P, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR. Aliment Pharmacol Ther; 2012 Aug; 36(3):239-47. PubMed ID: 22670722 [Abstract] [Full Text] [Related]
2. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. Shah R, Richardson P, Yu H, Kramer J, Hou JK. Digestion; 2017 Aug; 95(3):188-193. PubMed ID: 28288458 [Abstract] [Full Text] [Related]
3. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M. Gastroenterology; 2012 Aug; 143(2):375-81.e1; quiz e13-4. PubMed ID: 22522090 [Abstract] [Full Text] [Related]
4. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. Mainie I, Tutuian R, Castell DO. J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394 [Abstract] [Full Text] [Related]
5. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424 [Abstract] [Full Text] [Related]
6. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Gastroenterology; 2012 Aug; 143(2):382-9. PubMed ID: 22609382 [Abstract] [Full Text] [Related]
7. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, Vatn MH, Moum B, Ibsen Study Group. Scand J Gastroenterol; 2006 Sep; 41(9):1037-43. PubMed ID: 16938716 [Abstract] [Full Text] [Related]
8. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK. Aliment Pharmacol Ther; 2009 Apr 15; 29(8):843-54. PubMed ID: 19154567 [Abstract] [Full Text] [Related]
9. [Incidence and prevalence of inflammatory bowel disease. Asturian study in 5 areas (EIICEA). Spain]. Saro Gismera C, Riestra Menéndez S, Milla Crespo A, Sánchez Fernández R, Lacort Fernández M, Argüelles Fernández G, Chovac Z, Florido Mancheño JI, Antón Magarzo JL, Altadill Arregui A, Vizoso F, Pineda García E, Fernández de Ocariz Archs E, Albert Colomer J, García Pérez J, López Rivas L, Lombraña JL. An Med Interna; 2003 Jan 15; 20(1):3-9. PubMed ID: 12666301 [Abstract] [Full Text] [Related]
10. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P, DCCD study group. Am J Gastroenterol; 2006 Jun 15; 101(6):1274-82. PubMed ID: 16771949 [Abstract] [Full Text] [Related]
11. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Jess T, Frisch M, Simonsen J. Clin Gastroenterol Hepatol; 2013 Jan 15; 11(1):43-8. PubMed ID: 23022699 [Abstract] [Full Text] [Related]
12. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T, IBSEN Group. Gut; 2013 Mar 15; 62(3):368-75. PubMed ID: 22717453 [Abstract] [Full Text] [Related]
13. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Am J Gastroenterol; 1999 Nov 15; 94(11):3248-53. PubMed ID: 10566724 [Abstract] [Full Text] [Related]
14. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Riis L, Vind I, Politi P, Wolters F, Vermeire S, Tsianos E, Freitas J, Mouzas I, Ruiz Ochoa V, O'Morain C, Odes S, Binder V, Moum B, Stockbrügger R, Langholz E, Munkholm P, European Collaborative study group on Inflammatory Bowel Disease. Am J Gastroenterol; 2006 Jul 15; 101(7):1539-45. PubMed ID: 16863558 [Abstract] [Full Text] [Related]
15. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Am J Gastroenterol; 2009 Feb 15; 104(2):371-83. PubMed ID: 19174787 [Abstract] [Full Text] [Related]
17. The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. Ott C, Obermeier F, Thieler S, Kemptner D, Bauer A, Schölmerich J, Rogler G, Timmer A. Eur J Gastroenterol Hepatol; 2008 Sep 15; 20(9):917-23. PubMed ID: 18794607 [Abstract] [Full Text] [Related]
18. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist? Hashimoto H, Kushikata T, Kudo M, Hirota K. J Gastroenterol; 2007 Apr 15; 42(4):275-8. PubMed ID: 17464455 [Abstract] [Full Text] [Related]
19. Risk of arterial thrombotic events in inflammatory bowel disease. Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Am J Gastroenterol; 2009 Jun 15; 104(6):1445-51. PubMed ID: 19491858 [Abstract] [Full Text] [Related]